5 FDA Decisions to Watch in the Second Half of 2024
The next six months for the FDA are primed to be as groundbreaking as the first six, with Eli Lilly’s donanemab and Lykos Therapeutics’ MDMA-assisted PTSD therapy on the docket, among others.
5 FDA Decisions to Watch in the Second Half of 2024 Read More »
